Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial

Abstract Background and Aims Ulcerative colitis [UC] impacts patients’ health-related quality of life [HRQoL]. We assessed HRQoL and an exploratory patient-level composite endpoint (‘Comprehensive Disease Control’ [CDC]) in individuals receiving filgotinib [an oral JAK1 preferential inhibitor] in th...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of Crohn's and colitis 2023-06, Vol.17 (6), p.863-875
Hauptverfasser:	Schreiber, Stefan, Feagan, Brian G, Peyrin-Biroulet, Laurent, Vermeire, Séverine, Faes, Margaux, Harris, Kristina, Oortwijn, Alessandra, Daniele, Patrick, Patel, Haridarshan, Danese, Silvio
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Biological Products - therapeutic use Colitis, Ulcerative - drug therapy Double-Blind Method Humans Janus Kinase Inhibitors - therapeutic use Original Pyridines - therapeutic use Quality of Life
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!